GlassScriptPhysician profile
Tania Jain
NPI 1831486307
$95,144.25
in general payments reported to CMS, 2019-2025
17 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.65 · 2020: $3,000 · 2021: $2,153 · 2022: $14K · 2023: $12K · 2024: $31K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Travel and Lodging: $12K · Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,342.25 |
| Travel and Lodging | $11,711.91 |
| Food and Beverage | $1,836.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $23,541.13 | 2021-2025 | |
| Kite Pharma, INC. | $18,545.84 | 2024-2025 | Yescarta |
| Celgene Corporation | $12,777.12 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $12,073.18 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11,192.11 | 2023-2025 | |
| Abbvie INC. | $8,144.18 | 2022-2024 | |
| Blueprint Medicines Corporation | $3,315.15 | 2022-2023 | Ayvakit |
| Morphosys, US INC. | $2,157.92 | 2023 | |
| Novartis Pharmaceuticals Corporation | $1,542.64 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $1,000.00 | 2023 | Carvykti |
| National Marrow Donor Program | $370.87 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $196.29 | 2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $96.65 | 2019 | |
| Pharmaessentia USA Corporation | $94.55 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $82.68 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.94 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.